Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
The IBB biotech ETF is drawing strong options activity Thursday, as news ranging from mergers to government regulation continues to rock the sector.
The Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.
With cash scarce, credit tight and big drug companies intent on branching into biotechnology themselves, struggling bio-tech start-ups may no longer get second and third chances to succeed from thier investors, the New York Times reports.
The final form of health-care reform is hardly clear, but Joel Sendek of Lazard Capital Markets says he's heard enough to point him toward some rewarding stock-market investments.
Amid the gloom, Birinyi Associates' Cleve Rueckert found what he sees as a bright spot in the stock market. In a note, he says growth is the place to be, based on performance of the S&P's Pure Growth Index versus the S&P Pure Value Index. Here's his list of 15 stocks in the S&P 500 that fit three key growth criteria.
Even though nearly every analyst this morning is saying Thursday's bloodbath was an overreaction, investors are continuing to sell biopharma stocks in the early going Friday.
Beating the market is great, but for the moment your goal should be withstanding the market. Here's how you do it.
Want to make it through this recession with as much net worth as possible? Then buy these stocks.
With the markets testing new lows, here are the [surviving] S&P 500 companies that have fallen / gained the most since the market peaked on October 9, 2007.
On Friday Disney launched Disney XD in 72 million homes, a new ad-supported basic cable channel targeting boys age six to fourteen.
Hey, China got it right. Why couldn't we?
CNBC's "Power Lunch" team asked some of the best and the brightest from America's big financial firms to list the most promising stocks. Strategists from Citigroup, Goldman Sachs, Cowen & Co. and Deutsche Bank offered CNBC their stock picks.
No doubt this market’s bad. But cashing out is not the answer.
Is it time for investors to feast on food stocks? David Palmer thinks that's a reasonable assumption. "They're a decent place to be," the UBS senior restaurant analyst told CNBC. "Input costs are coming off their highs; certainly, people have to eat, so, as people look for cheaper calories, (packaged food companies) should be doing OK."
These days the most cash-rich companies often sell mobile phones rather than mortgages. Cramer tells you who's who in the changing market landscape.
Stocks ended higher Tuesday, snapping a three-day losing streak, after strong earnings from Merck and a better-than-expected housing report lifted sentiment on the Street.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Investors can’t help but wonder what’s the best way to play Pharma after Pfizer said it would buy rival Wyeth for $60 billion, a 20% premium!
A recession-resistant play with a nice dividend yield in a period of declining commodity prices? Maybe.
Happy Birthday By The Numbers! Today is the first anniversary of the launch of By The Numbers. We debuted in January 2008 as a top ten CNBC.com blog, and shortly after, were awarded an internal recognition as the "Fastest Growing Blog."